QIAGEN N.V. Files Q1 2024 6-K Report

Ticker: QGEN · Form: 6-K · Filed: May 1, 2024 · CIK: 1015820

Qiagen N.V. 6-K Filing Summary
FieldDetail
CompanyQiagen N.V. (QGEN)
Form Type6-K
Filed DateMay 1, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: quarterly-report, foreign-private-issuer

Related Tickers: QGEN

TL;DR

QIAGEN dropped its Q1 2024 6-K, check it for performance updates.

AI Summary

QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2024. The filing is a report of a foreign private issuer and includes information on other matters, signatures, and an exhibit index. The company's principal executive office is located in Venlo, The Netherlands.

Why It Matters

This filing provides an update on QIAGEN's financial reporting for the first quarter of 2024, which is crucial for investors to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This filing is a routine quarterly report and does not contain significant new risks or material adverse events.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public pursuant to the laws of its home country or jurisdiction, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

What period does this specific 6-K filing cover?

This specific Form 6-K filing covers the quarterly period ended March 31, 2024.

Where is QIAGEN N.V.'s principal executive office located?

QIAGEN N.V.'s principal executive office is located at Hulsterweg 82, 5912 PL Venlo, The Netherlands.

What is the Commission File Number for QIAGEN N.V.?

The Commission File Number for QIAGEN N.V. is 001-38332.

Does QIAGEN N.V. file annual reports under Form 20-F or 40-F?

QIAGEN N.V. indicates that it files annual reports under cover of Form 20-F.

Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-04-30 17:58:46

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date April 30, 2024 4 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press Release dated April 29, 2024 5

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing